Gilead and Teva prevail in $3.6bn antitrust trial


Marisa Woutersen

Gilead and Teva prevail in $3.6bn antitrust trial

Sundry Photography /

Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.

Gilead Sciences and Teva Pharmaceuticals Industries have received a favourable verdict in an HIV antitrust trial in the US District Court for the Northern District of California.

The lawsuit, brought by consumers and direct purchasers, including the Blue Cross and Blue Shield Association, accused Gilead of maintaining a monopoly in the HIV drug market by unlawfully extending patent protection to delay generic competition.

The plaintiffs sought $3.6 billion in damages.

Gilead Sciences, Teva Pharmaceuticals Industries, HIV, antitrust, US District Court, Deborah Telman, US